Abstract 240P
Background
This study aimed to investigate the role of the serpin peptidase inhibitor, clade E, member 2 (SERPINE2), in patients with oral squamous cell carcinoma (OSCC).
Methods
We investigated SERPINE2 mRNA expression in cases of squamous cell carcinoma from online databases, explored the relationship between SERPINE2 and clinicopathological characteristics and prognosis in OSCC patients, and determined the potential of SERPINE2 to affect OSCC proliferation, migration and invasion capability in vitro.
Results
The expressions of SERPINE2 were higher in tumor tissues than that in normal tissues in TNMplot. High mRNA expression of SERPINE2 was significantly correlated with poor overall 5-year survival in KmPlot. High SERPINE2 immunoexpression was significantly correlated with adverse pathologic parameters. High SERPINE2 immunoexpression was significantly associated with worse overall survival. SERPINE2 promotes cell proliferation, cell migration, and invasion ability in OSCC cell lines. Table: 240P
Relationships between the immunoscore of SERPINE2 and clinicopathological parameters in 122 patients
| Parameters | No. | Mean ± SEM | Median | p | |
| Agea | |||||
| ≤ 54 | 73 | 147.47 ± 7.77 | 160 | 0.132 | |
| > 54 | 49 | 163.83 ± 8.86 | 165 | ||
| Gendera | |||||
| Male | 107 | 152.59 ± 6.45 | 160 | 0.561 | |
| Female | 15 | 164.33 ± 13.21 | 160 | ||
| Tumor siteb | |||||
| Buccal | 77 | 152.08 ± 7.29 | 160 | 0.700 | |
| Retromolar | 24 | 148.96 ± 13.50 | 165 | ||
| Tongue | 7 | 170.36 ± 25.33 | 170 | ||
| Others | 14 | 165.36 ± 19.25 | 171 | ||
| Histological gradeb | |||||
| Well | 45 | 149.00 ± 8.18 | 165 | 0.720 | |
| Moderate | 71 | 156.13 ± 8.35 | 160 | ||
| Poor | 6 | 167.08 ± 30.81 | 183 | ||
| Stagea | |||||
| I–II | 66 | 133.60 ± 7.41 | 153 | <0.001* | |
| III–IV | 56 | 178.13 ± 8.34 | 184 | ||
| Tumor statusa | |||||
| T1–2 | 78 | 139.20 ± 7.18 | 160 | <0.001* | |
| T3–4 | 44 | 180.34 ± 8.98 | 186 | ||
| Nodal metastasisa | |||||
| Absent | 91 | 145.36 ± 6.39 | 160 | 0.011* | |
| Present | 31 | 179.52 ± 12.64 | 180 | ||
| Distant metastasisa | |||||
| Absent | 107 | 148.69 ± 6.36 | 160 | 0.010* | |
| Present | 15 | 192.17 ± 11.12 | 188 |
ap-value by Mann–Whitney U testbp-value by Kruskal–Wallis test. *Significance at p < 0.05
Conclusions
Our results suggest that SERPINE2 may serve as a prognostic biomarker, associated with the tumorigenesis and aggressiveness of OSCC, and a potential therapeutic target in oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This research was supported by a grant from Kaohsiung Veterans General Hospital (grant number VGHKS109-074) in Taiwan, ROC.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
265P - Tumor-agonistic genomic profiling
Presenter: Naomi Hayashi
Session: Poster viewing 03
266P - Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
Presenter: Xuchao Zhang
Session: Poster viewing 03
267P - Genomic landscape of non-small cell lung cancer (NSCLC) in India using circulating tumor DNA (ctDNA) in clinical practice
Presenter: Amit Rauthan
Session: Poster viewing 03
269P - MET alterations in EGFR mutated NSCLC: A lesser known evil
Presenter: Mansi Sharma
Session: Poster viewing 03
271P - Prospective study on toxicity profile of immunotherapy in a Indian population: A real-world experience
Presenter: Kaushik R
Session: Poster viewing 03